Vanguard Fiduciary Trust
MEDS

Vanguard Fiduciary Trust’s DataMeds AI MEDS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2K Sell
6,191
-1
-0% -$5 ﹤0.01% 3998
2026
Q1 		$29.7K Buy
+6,192
New +$85K ﹤0.01% 3899

Other funds holding MEDS

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Vanguard Fiduciary Trust's MEDS Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its DataMeds AI (MEDS) stake by 0.02% in Q2 2026, selling an estimated $5 and leaving 6,191 shares worth $19.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3998.

Vanguard Fiduciary Trust first reported a position in MEDS in Q1 2026 and has held it in 2 quarters since. The position peaked at $29.7K in Q1 2026. 9 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

  • Vanguard Fiduciary Trust held 6,191 shares of DataMeds AI worth $19.2K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 1 DataMeds AI share in Q2 2026, an estimated $5.
  • DataMeds AI made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3998 holding.
  • Vanguard Fiduciary Trust first reported a position in DataMeds AI in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's DataMeds AI position peaked at $29.7K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.